Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  van Doorn, Ruben ^a   Lopes Pinheiro, Melissa A ^a   Kooij, Gijs ^a   Lakeman, Kim ^a   van het Hof, Bert ^a   van der Pol, Susanne M A ^a   Geerts, Dirk ^b   van Horssen, Jack ^a   van der Valk, Paul ^a   van der Kam, Elizabeth ^c   Ronken, Eric ^d   Reijerkerk, Arie ^a   de Vries, Helga E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c ABBOTT GMBH AND CO KG   (Germany)

^d ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Blood brain barrier; FTY720P; Monocyte; Multiple sclerosis; Neuroinflammation; Sphingosine 1 phosphate (S1P) receptor

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BIOLOGICAL MARKER; FINGOLIMOD; FTY 270P; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 5; UNCLASSIFIED DRUG;

AGED; ARTICLE; AUTOPSY; BLOOD BRAIN BARRIER; CELL CULTURE; CELL FUNCTION; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LENTIVIRINAE; MALE; MONOCYTE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

EID: 84862327950     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-133     Document Type: Article

References (45)

1. Aronica E, Gorter JA, Redeker S, van Vliet EA, Ramkema M, Scheffer GL, Scheper RJ, van DV, Leenstra S, Baayen JC, et al. Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 2005, 46:849-857. 10.1111/j.1528-1167.2005.66604.x, 15946326.
2. Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999, 36:179-194. 10.1016/S0169-409X(98)00085-4, 10837715.
3. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001, 2:285-293. 10.1038/35067088, 11283726.
4. Balda MS, Flores-Maldonado C, Cereijido M, Matter K. Multiple domains of occludin are involved in the regulation of paracellular permeability. J Cell Biochem 2000, 78:85-96. 10.1002/(SICI)1097-4644(20000701)78:1<85::AID-JCB8>3.0.CO;2-F, 10797568.
5. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006, 7:41-53. 10.1038/nrn1824, 16371949.
6. Vos CM, Geurts JJ, Montagne L, van Haastert ES, Bo L, van DV, Barkhof F, De Vries HE. Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. Neurobiol Dis 2005, 20:953-960. 10.1016/j.nbd.2005.06.012, 16039866.
7. Carrano A, Hoozemans JJ, van der Valk P, Rozemuller AJ, van Horssen J, De Vries HE. Amyloid beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal 2011, 15:1167-1178. 10.1089/ars.2011.3895, 21294650.
8. Eugenin EA, Clements JE, Zink MC, Berman JW. Human immunodeficiency virus infection of human astrocytes disrupts blood-brain barrier integrity by a gap junction-dependent mechanism. J Neurosci 2011, 31:9456-9465. 10.1523/JNEUROSCI.1460-11.2011, 3132881, 21715610.
9. Avison MJ, Nath A, Greene-Avison R, Schmitt FA, Greenberg RN, Berger JR. Neuroimaging correlates of HIV-associated BBB compromise. J Neuroimmunol 2004, 157:140-146. 10.1016/j.jneuroim.2004.08.025, 15579291.
10. Kooij G, van HJ, de Lange EC, Reijerkerk A, van der Pol SM, Van Het HB, Drexhage J, Vennegoor A, Killestein J, Scheffer G, et al. T lymphocytes impair P-glycoprotein function during neuroinflammation. J Autoimmun 2010, 34:416-425. 10.1016/j.jaut.2009.10.006, 19959334.
11. Sobel RA, Hinojoza JR, Maeda A, Chen M. Endothelial cell integrin laminin receptor expression in multiple sclerosis lesions. Am J Pathol 1998, 153:405-415. 10.1016/S0002-9440(10)65584-8, 1852968, 9708801.
12. Schreibelt G, Musters RJ, Reijerkerk A, de Groot LR, van der Pol SM, Hendrikx EM, Dopp ED, Dijkstra CD, Drukarch B, De Vries HE. Lipoic acid affects cellular migration into the central nervous system and stabilizes blood-brain barrier integrity. J Immunol 2006, 177:2630-2637.
13. Toman RE, Spiegel S. Lysophospholipid receptors in the nervous system. Neurochem Res 2002, 27:619-627. 10.1023/A:1020219915922, 12374197.
14. Allende ML, Proia RL. Sphingosine 1-phosphate receptors and the development of the vascular system. Biochim Biophys Acta 2002, 1582:222-227. 10.1016/S1388-1981(02)00175-0, 12069832.
15. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002, 277:21453-21457. 10.1074/jbc.C200176200, 11967257.
16. Hasegawa Y, Suzuki H, Sozen T, Rolland W, Zhang JH. Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. Stroke 2010, 41:368-374. 10.1161/STROKEAHA.109.568899, 2811754, 19940275.
17. Shichita T, Sugiyama Y, Ooboshi H, Sugimori H, Nakagawa R, Takada I, Iwaki T, Okada Y, Iida M, Cua DJ, et al. Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med 2009, 15:946-950. 10.1038/nm.1999, 19648929.
18. Zhang ZY, Zhang Z, Schluesener HJ. FTY720 attenuates lesional interleukin-17(+) cell accumulation in rat experimental autoimmune neuritis. Neuropathol Appl Neurobiol 2009, 35:487-495. 10.1111/j.1365-2990.2009.01016.x, 19207263.
19. Foster CA, Mechtcheriakova D, Storch MK, Balatoni B, Howard LM, Bornancin F, Wlachos A, Sobanov J, Kinnunen A, Baumruker T. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol 2009, 19:254-266. 10.1111/j.1750-3639.2008.00182.x, 18540945.
20. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362:387-401. 10.1056/NEJMoa0909494, 20089952.
21. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362:402-415. 10.1056/NEJMoa0907839, 20089954.
22. Sanchez T, Estrada-Hernandez T, Paik JH, Wu MT, Venkataraman K, Brinkmann V, Claffey K, Hla T. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 2003, 278:47281-47290. 10.1074/jbc.M306896200, 12954648.
23. Mullershausen F, Craveiro LM, Shin Y, Cortes-Cros M, Bassilana F, Osinde M, Wishart WL, Guerini D, Thallmair M, Schwab ME, et al. Phosphorylated FTY720 promotes astrocyte migration through sphingosine 1-phosphate receptors. J Neurochem 2007, 102:1151-1161. 10.1111/j.1471-4159.2007.04629.x, 17488279.
24. Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, Teo ST, Yung YC, Lu M, Kennedy G, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci USA 2011, 108:751-756. 10.1073/pnas.1014154108, 3021041, 21177428.
25. Van Doorn R, van Horssen J, Verzijl D, Witte M, Ronken E, Van het Hof B, Lakeman K, Dijkstra CD, van der Valk P, Reijerkerk A, et al. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia 2010, 58:1465-1476.
26. van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra CD, van der Valk P, De Vries HE. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med 2008, 45:1729-1737. 10.1016/j.freeradbiomed.2008.09.023, 18930811.
27. Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 2005, 19:1872-1874.
28. Reijerkerk A, Kooij G, van der Pol SM, Khazen S, Dijkstra CD, De Vries HE. Diapedesis of monocytes is associated with MMP-mediated occludin disappearance in brain endothelial cells. FASEB J 2006, 20:2550-2552. 10.1096/fj.06-6099fje, 17065217.
29. Reijerkerk A, Lakeman KA, Drexhage JA, Van Het HB, Van WY, van der Pol SM, Kooij G, Geerts D, De Vries HE. Brain endothelial barrier passage by monocytes is controlled by the endothelin system. J Neurochem 2012, 121:730-737. 10.1111/j.1471-4159.2011.07393.x, 21777246.
30. Garcia-Vallejo JJ, van DW, Van Het HB, van DI, Engelse MA, Van HV, Gringhuis SI. Activation of human endothelial cells by tumor necrosis factor-alpha results in profound changes in the expression of glycosylation-related genes. J Cell Physiol 2006, 206:203-210. 10.1002/jcp.20458, 16080149.
31. Hanessian S, Charron G, Billich A, Guerini D. Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors. Bioorg Med Chem Lett 2007, 17:491-494. 10.1016/j.bmcl.2006.10.014, 17070046.
32. Elkord E, Williams PE, Kynaston H, Rowbottom AW. Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells. Immunology 2005, 114:204-212. 10.1111/j.1365-2567.2004.02076.x, 1782075, 15667565.
33. De Vries HE, Hendriks JJ, Honing H, De Lavalette CR, van der Pol SM, Hooijberg E, Dijkstra CD, van den Berg TK. Signal-regulatory protein alpha-CD47 interactions are required for the transmigration of monocytes across cerebral endothelium. J Immunol 2002, 168:5832-5839.
34. Binnerts ME, van KY, Simmons DL, Figdor CG. Distinct binding of T lymphocytes to ICAM-1, -2 or -3 upon activation of LFA-1. Eur J Immunol 1994, 24:2155-2160. 10.1002/eji.1830240933, 7916295.
35. Floris S, Ruuls SR, Wierinckx A, van der Pol SM, Dopp E, van der Meide PH, Dijkstra CD, De Vries HE. Interferon-beta directly influences monocyte infiltration into the central nervous system. J Neuroimmunol 2002, 127:69-79. 10.1016/S0165-5728(02)00098-X, 12044977.
36. Camp SM, Bittman R, Chiang ET, Moreno-Vinasco L, Mirzapoiazova T, Sammani S, Lu X, Sun C, Harbeck M, Roe M, et al. Synthetic analogs of FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] differentially regulate pulmonary vascular permeability in vivo and in vitro. J Pharmacol Exp Ther 2009, 331:54-64. 10.1124/jpet.109.153544, 2766218, 19592667.
37. Dudek SM, Camp SM, Chiang ET, Singleton PA, Usatyuk PV, Zhao Y, Natarajan V, Garcia JG. Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor. Cell Signal 2007, 19:1754-1764. 10.1016/j.cellsig.2007.03.011, 2682440, 17475445.
38. Sarai K, Shikata K, Shikata Y, Omori K, Watanabe N, Sasaki M, Nishishita S, Wada J, Goda N, Kataoka N, et al. Endothelial barrier protection by FTY720 under hyperglycemic condition: involvement of focal adhesion kinase, small GTPases, and adherens junction proteins. Am J Physiol Cell Physiol 2009, 297:C945-C954. 10.1152/ajpcell.00606.2008, 19657053.
39. Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, Volpi M, Sha'afi RI, Hla T. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 1999, 99:301-312. 10.1016/S0092-8674(00)81661-X, 10555146.
40. Keul P, Tolle M, Lucke S, von Wnuck LK, Heusch G, Schuchardt M, der GM V, Levkau B. The sphingosine 1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2007, 27:607-613. 10.1161/01.ATV.0000254679.42583.88, 17158351.
41. Wei Y, Yemisci M, Kim HH, Yung LM, Shin HK, Hwang SK, Guo S, Qin T, Alsharif N, Brinkmann V, et al. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol 2011, 69:119-129. 10.1002/ana.22186, 3200194, 21280082.
42. Krump-Konvalinkova V, Yasuda S, Rubic T, Makarova N, Mages J, Erl W, Vosseler C, Kirkpatrick CJ, Tigyi G, Siess W. Stable knock-down of the sphingosine 1-phosphate receptor S1P1 influences multiple functions of human endothelial cells. Arterioscler Thromb Vasc Biol 2005, 25:546-552. 10.1161/01.ATV.0000154360.36106.d9, 15618544.
43. Nofer JR, Geigenmuller S, Gopfert C, Assmann G, Buddecke E, Schmidt A. High density lipoprotein-associated lysosphingolipids reduce E-selectin expression in human endothelial cells. Biochem Biophys Res Commun 2003, 310:98-103. 10.1016/j.bbrc.2003.08.126, 14511654.
44. Bolick DT, Srinivasan S, Kim KW, Hatley ME, Clemens JJ, Whetzel A, Ferger N, Macdonald TL, Davis MD, Tsao PS, et al. Sphingosine 1-phosphate prevents tumor necrosis factor-{alpha}-mediated monocyte adhesion to aortic endothelium in mice. Arterioscler Thromb Vasc Biol 2005, 25:976-981. 10.1161/01.ATV.0000162171.30089.f6, 15761190.
45. Niedernberg A, Blaukat A, Schoneberg T, Kostenis E. Regulated and constitutive activation of specific signalling pathways by the human S1P5 receptor. Br J Pharmacol 2003, 138:481-493. 10.1038/sj.bjp.0705055, 1573682, 12569073.